logo

Protagonist Therapeutics, Inc (PTGX)



Trade PTGX now with
  Date
  Headline
12/13/2018 7:04:41 AM Protagonist Therapeutics Initiates Phase 1 Trial Of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
10/22/2018 8:36:53 AM Protagonist Therapeutics Presents Clinical Data From PROPEL Study Of PTG-100 In Ulcerative Colitis
10/8/2018 7:15:29 AM Protagonist Therapeutics: William Sandborn To Present Clinical Data From Phase 2 Study Of PTG-100
9/27/2018 7:06:52 AM Protagonist Therapeutics Announces Fast Track Designation Granted By U.S. FDA To Hepcidin Mimetic PTG-300
9/6/2018 7:05:24 AM Protagonist Therapeutics Receives $1.45 Mln SBIR Funding For Development Of PTG-300
6/18/2018 7:08:12 AM Protagonist Announces Phase 1 And Pre-clinical Data On Hepcidin Mimetic PTG-300 Presented At EHA Annual Meeting
6/1/2018 7:05:09 AM Protagonist Therapeutics Reports Granting Of Inducement Award To Samuel Saks, Chief Development Officer
5/24/2018 4:33:13 PM Protagonist Therapeutics Names Samuel Saks As Chief Development Officer
3/26/2018 6:46:07 AM Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial Of PTG-100 For Ulcerative Colitis
3/7/2018 4:04:49 PM Protagonist Therapeutics Q4 Loss/share $0.15 Vs. Loss $0.67 Year Ago
1/4/2018 8:13:22 AM Protagonist Therapeutics Receives Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300